The presence of GPC-1 on GBM cells U-251 and U-87 was confirmed by flow cytometry, compared to GPC-1-negative cell line Raji and analyzed using the murine version of Miltuximab®, antibody MIL-38 (GlyTherix Ltd., Sydney, Australia), and QIFIKIT (Quantitative Immunofluorescence Intensity kit, Dako) that allows quantification of surface-bound molecules. Here, GPC1 is linked to glioblastoma.